Recommended NZ | Guide to Money | Gimme: Competitions - Giveaways

Atopic dermatitis market review - Botanix Pharmaceuticals

Fuseworks Media
Fuseworks Media

Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, "Botanix" or the "Company") is pleased to release a presentation made at its Advisory Board meeting held on 22 May 2018. The presentation focused on the dynamics of the growing atopic dermatitis market, the positioning of the Company’s BTX 1204 product and sought feedback from key advisers, ahead of the completion of data processing and release from the recently completed Phase 1b BTX 1204 study.

Botanix Executive Director Matt Callahan stated "the updated view on the global atopic dermatitis market underpins the compelling potential of BTX 1204. There is a significant market opportunity for an atopic dermatitis treatment which has an improved safety profile, improves lesion resolution and has the ability to be utilised in the long term."

Botanix has successfully completed the treatment phase of all patients enrolled in the BTX 1204 Phase 1b study and is actively processing the study data and is on track to release the results in June 2018.

About Atopic Dermatitis

Atopic dermatitis is a common, relapsing, chronic inflammatory skin disorder. Patients display a chronic rash characterised by inflammation and itching, which often occurs in folds of the skin with symptoms lasting up to 14 days or more. Approximately 25m people in the US suffer from this condition, including between 8% to 18% of infants and children. Atopic dermatitis has been considerably under-diagnosed due to the lack of approved effective systemic agents, and limitations of current topical agents.

Before the recent approval of Eucrisa (crisaborole), there had been no new drugs approved for atopic dermatitis for more than 15 years and based on successful Phase 3 studies, Pfizer acquired the company that developed Eucrisa (Anacor Pharmaceuticals Inc.) for US$5.2bn in May 2016. Clinical studies showed that Eucrisa had little to no impact on itch, which remains a key unmet need for atopic dermatitis patients.

All articles and comments on have been submitted by our community of users. Please notify us if you believe an item on this site breaches our community guidelines.